Kazia Therapeutics

This cancer drug developer has Paxalisib as its lead candidate. Paxalisib works by hitting a cellular signalling pathway called PI3K / Akt / mTOR that is a central regulator of growth and cell division. It can go badly wrong when cancer gets started. The drug is being evaluated in eight clinical studies but, significantly, it entered Phase 3 in glioblastoma, the most common of the primary brain cancers, with the commencement of the GBM AGILE study in January 2021. We think Kazia’s maturity can p...

Save $$$
30-Day Free Trial
$0
No Credit Card Required!
Get access to 4 publications
Weekly Investor Webinar
Access to Marc & Stuart's Top Picks
Profit Premium
$69
Get access to 4 publications
Access to the full research Archive
Weekly Investor Webinar
Access to Marc & Stuart's Top Picks
30-Day Free Trial
$0
No Credit Card Required!
Get access to 4 publications
Weekly Investor Webinar
Access to Marc & Stuart's Top Picks
Profit Premium
$59
BILLED ANNUALLY
Get access to 4 publications
Access to the full research Archive
Weekly Investor Webinar
Access to Marc & Stuart's Top Picks